Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;143(5):609-612.
doi: 10.1007/s00401-022-02415-6. Epub 2022 Mar 31.

Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study

Affiliations

Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study

Areeba Patel et al. Acta Neuropathol. 2022 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Rapid-CNS2 timeline and concordance with standard methods. Timeline for a NGS panel sequencing and analysis pipeline, and b EPIC array analysis pipeline for neuropathology diagnostics (x denotes number of days required to pool sufficient samples). c Timeline for Rapid-CNS2 sequencing and analysis for a single sample on a MinION or up to five samples on a GridION. d Concordance of clinically relevant alterations and classification for diffuse glioma samples with matching NGS panel sequencing and EPIC array analysis. Colored blocks indicate presence of alteration, concordance for detected alterations is denoted in the legend. Triangular denotations for methylation class indicate samples where methylation families were concordant and blocks indicate concordance for sub-classes as well. ‘PANEL_A’ indicates samples sequenced using Rapid_CNS_A, and ‘PANEL_B’ indicates samples sequenced using Rapid_CNS_B (sample by Rapid-CNS2 and 850 k identified as AT/RT excluded, depicted in Supplementary Fig. 4, online resource). Top barplot indicates mean on-target coverage. Red asterisk—different tissue region for Rapid-CNS2 vs conventional analyses, purple asterisk—alteration filtered by PEPPER-Margin-DeepVariant (see main text for details)

References

    1. Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124:547–560. doi: 10.1007/s00401-012-1016-2. - DOI - PMC - PubMed
    1. Bowden R, Davies RW, Heger A, Pagnamenta AT, de Cesare M, Oikkonen LE, et al. Sequencing of human genomes with nanopore technology. Nat Commun. 2019;10:1869. doi: 10.1038/s41467-019-09637-5. - DOI - PMC - PubMed
    1. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474. doi: 10.1038/nature26000. - DOI - PMC - PubMed
    1. Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau M, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol. 2017;134:691–703. doi: 10.1007/s00401-017-1743-5. - DOI - PMC - PubMed
    1. Gorzynski JE, Goenka SD, Shafin K, Jensen TD, Fisk DG, Grove ME, et al. Ultrarapid nanopore genome sequencing in a critical care setting. N Engl J Med. 2022;386:700–702. doi: 10.1056/NEJMc2112090. - DOI - PubMed

Publication types

LinkOut - more resources